Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a weekly pill stop STIs? new study tests doxycycline in kenyan women

NCT ID NCT06582966

Prevention Sponsor: University of Washington Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested whether taking doxycycline once a week can prevent bacterial sexually transmitted infections (STIs) in cisgender women who are already taking HIV PrEP. Sixty women in Kisumu, Kenya, received the antibiotic weekly under direct observation for six months. The main goal was to see how well they stuck to the regimen and whether they found it acceptable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
doxycycline
What this could lead to
If successful, this could point toward a simple weekly pill to help prevent bacterial STIs in women at risk.
What could go wrong
This is a small pilot study with only 60 participants and no control group, so results may not apply broadly. Adherence and side effects could limit effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

60 people

The number who actually took part.

Started

Aug 2024

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 30 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Willing and able to give written informed consent 2. Age 18-30 years 3. Female sex assigned at birth 4. HIV-seronegative, according to national HIV testing algorithm 5. Has a current prescription for PrEP, \> 1 month, according to the national guidelines of Kenya Exclusion Criteria: 1. Pregnant 2. Breastfeeding a child 3. Allergy to tetracycline class 4. Current medications which may impact doxycycline metabolism or that are contraindicated with doxycycline, as per the prescribing information. These include systemic retinoids, barbiturates, carbamazepine, phenytoin, and warfarin. 5. Active, clinically significant medical or psychiatric conditions that would interfere with study participation, at the discretion of the site investigator or designee. 6. Prior enrollment in The dPEP Kenya Study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STI are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

sexually transmitted disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STI

Contacts and locations

Locations

  • Kenya Medical Research Institute -KEMRI

    Kisumu, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.